Rare Kidney Diseases : Market Size, Share & Trends Analysis, Segment, Current Scenario, Regional Outlook and Major Companies, Key Devlopment, forecast period for 2024-2031.

According to the latest research the global market for uncommon kidney diseases is expected to show a promising Compound Annual Growth Rate (CAGR) of 9.91% from 2024to 2031.

Request Sample Report Download @ https://www.insightaceanalytic.com/request-sample/1414

Approximately 150 distinct conditions are included in rare renal diseases (RKD). The prevalence of rare renal diseases is estimated to be between 60 and 80 per 100 000 cases/individuals in the United States (US) and Europe. Kidney disease may be present in approximately one-third of adults with diabetes and one-fifth of adults with hypertension. In 2018 kidney diseases resulted in a more significant number of fatalities than breast and prostate malignancies combined (NVS 2021 report of 2018 data). Patients with kidney disease are five to ten times more likely to perish prematurely than to develop kidney failure with replacement therapy (KFRT). It is crucial to acknowledge that the treatment of individuals with rare renal diseases became significantly more challenging following the onset of the COVID-19 pandemic. This is primarily because the majority of current treatments for these conditions necessitate frequent visits to the hospital or medical centre. This led to a 30% increase in the mortality rate of sick individuals during the pandemic. The pharmaceutical industry has been compelled to conduct the necessary research to identify new drugs that can effectively treat rare kidney diseases as a result of the increase in mortality rates.

The market for rare renal diseases is experiencing growth due to a number of critical factors. The expansion of the need for complex maladies is a result of the collaborative interactions among clinicians patients industry representatives regulatory agents and government agencies which are facilitated by new advancements in diagnosis and treatment. In addition the anticipated benefits of the expanded utilization of next-generation sequencing techniques include the enhancement of diagnostic accuracy for rare kidney diseases the elucidation of molecular mechanisms of disease the facilitation of genetic counseling and the provision of opportunities for carrier testing. At the cost of their quality of life patients are able to live longer due to the increased accessibility and advancements in renal replacement therapy.

Enquiry Before Buying Here @ https://www.insightaceanalytic.com/enquiry-before-buying/1414

Unresolved genetic defects a lack of biomarkers to monitor disease progression heterogeneous clinical phenotypes and obsolete diagnostic classifications that do not accurately reflect the underlying pathophysiological mechanisms are among the market-restraining factors that have impeded therapeutic advancements in rare kidney diseases. The market's development will also be restricted by the complex studies and slow drug approvals.
Rapid clinical advancements and research into kidney disease treatments in North America will result in its dominance and leadership in the global market for rare kidney diseases during the forecasted period.

The key market players are

• Amicus Therapeutics
• Alexion Pharmaceuticals (A subsidiary of AstraZeneca)
• Travere Therapeutics
• Calliditas Therapeutics
• AstraZeneca
• Advicenne
• Protalix Biotherapeutics
• Recordati Rare Diseases
• Reata Pharmaceuticals
• Aurinia Pharmaceutical
• Apellis Pharmaceuticals
• Chinook Therapeutics
• Novartis Pharmaceuticals
• Roche
• Merk & co.
• Omeros Corporation

Buy Report Directly here @ https://www.insightaceanalytic.com/buy-report/1414

Key Developments in The Market:

• In August 2022, CSL Vifor and Travere Therapeutics announced that the European Medicines Agency (EMA) has accepted the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN, a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
• In December 2021, the FDA approved the first drug to reduce urine protein levels in IgA nephropathy, a rare kidney disease. Adults with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression have been granted accelerated approval by the FDA for Tarpeyo (budesonide) delayed-release capsules, which are intended to reduce proteinuria (increased protein levels in the urine).
• In September 2021, Allarity Therapeutics and Lonza reached an agreement to collaborate on the development and manufacturing of dovitinib, Allarity's candidate therapy for renal cell carcinoma. The agreement stipulated that dovitinib manufacturing would commence in 2022 to satisfy Allarity's anticipated requirements for the commercialization of dovitinib following regulatory approvals.
• In June 2021, Novartis disclosed new interim Phase II data for iptacopan in the rare kidney disease C3 glomerulopathy (C3G). C3Gand (IgAN) IgA nephropathy, the blood disorder paroxysmal nocturnal hemoglobinuria (PNH), and a number of complement-driven renal diseases, including Iptacopan is being developed with the objective of addressing a critical driver of these diseases.

Request For Customization @ https://www.insightaceanalytic.com/customisation/1414

Market Segmentation

Global Rare Kidney Diseases Market, by Target Indication
• C3 Glomerulopathy
• Focal Segmental Glomerular Sclerosis
• Membranous Nephropathy
• IgA Nephropathy
• Dense Deposit Disease
• Atypical Hemolytic Uremic Syndrome
• Lupus Nephritis
• Cystinosis
• Distal Renal Tubular Acidosis
• Fabry Disease
• Refractory Gout
• Others

Global Rare Kidney Diseases Market, by Type of Molecule
• Small Molecules
• Biologics
o Monoclonal Antibody
o Recombinant Protein
o Hormone
o Others

Global Rare Kidney Diseases Market, by Route of Administration
• Intravenous
• Oral
• Subcutaneous
• Others

Global Rare Kidney Diseases Market, by Region
• North America
• Middle East & Africa
• Asia Pacific
• Europe
• Latin America

North America Rare Kidney Diseases Market, by Country
• Canada
• U.S.

Europe Rare Kidney Diseases Market, by Country
• France
• Rest of Europe
• Italy
• Germany
• Spain
• Russia

Asia Pacific Rare Kidney Diseases Market, by Country
• Australia & New Zealand
• China
• Japan
• India
• South Korea

Latin America Rare Kidney Diseases Market, by Country
• Mexico
• Brazil
• Rest of Latin America

Middle East & Africa Rare Kidney Diseases Market, by Country
• Rest of Middle East & Africa
• GCC Countries
• South Africa

View Full Report Here @ https://www.insightaceanalytic.com/report/global-rare-kidney-diseases-market-/1414

Contact Us:

InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis of key market insights in a timely and cost-effective manner.

This release was published on openPR.